A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
← catalyst calendarNCT07606066 · readout in 224 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,150estimated
Sites
71
Countries
Brazil, Hungary, India +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-06 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Intervention
- Other: Procedure: assessment
Primary outcomes
what the primary-completion date above is the date OFPatient demographics
measured Visit 1 (Single day)
Medical and surgical history
measured Visit 1 (Single day)
Concomitant medication
measured Visit 1 (Single day)
HbA1c levels
measured Visit 1 (Single day)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed